Opinion
Video
Author(s):
A panel of experts in prostate cancer present the case of a 51-year-old man with high-risk localized prostate cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Combination therapy linked to longer OS vs ADT in veterans with mHSPC
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Dr. Murphy on increasing diversity in cancer clinical trials
Study shows value of precision-based approaches in prostate cancer
SBRT may offer a safe alternative to CFRT after prostatectomy
Subcutaneous nivolumab approved in EU, Canada for solid tumors
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy
Application submitted to FDA for 510(k) clearance of Men’s Sexual Health Test